drugset / Trial / NCT01148537

The Effect of Buprenorphine Delivered by Buprenorphine Transdermal System (BTDS) on QT Intervals in Healthy Volunteers

NCT01148537

Phase 1 Completed 132 enrolled Purdue Pharma LP
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to examine the effect of buprenorphine on QT interval corrected for heart rate (QTc) in healthy subjects.

Timeline

Start
2004-07
Primary completion
2004-12
Completion
2004-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Buprenorphine Other / unclassified 5 ug Other
Subject Buprenorphine Other / unclassified 10 ug Other
Subject Buprenorphine Other / unclassified 20 ug Other
Subject Buprenorphine Other / unclassified 40 ug Other
Comparator Moxifloxacin Small molecule 400 mg Oral

Indications

No indication recorded.